Monashee Scales Back Structure: GPCR Bet Reassessed
A major hedge fund slashed its stake in Structure Therapeutics, prompting questions about the future path for GPCR-fo...
A straightforward rationale for incorporating Equal Weighted Indices into a portfolio, emphasizing diversification and simplicity.
22,501 articlesA major hedge fund slashed its stake in Structure Therapeutics, prompting questions about the future path for GPCR-fo...
Investors weighing risk and return should consider meta platforms might good as a long-term hold. This guide breaks d...
As EV demand grows and policy shifts unfold, investors are sizing up 2026. This guide breaks down the chances of a re...
Vertex Pharmaceuticals just made aBold move that could reshape its growth trajectory. This guide breaks down the deal...
A major investment manager disclosed a sizable share disposal in a U.S. utility stock through an SEC filing. The move...
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Big funds sometimes trim stakes in the market's most valuable names. This article breaks down why institutional inves...
When leaders sell stock alongside stronger earnings, investors should look beyond headlines. This guide breaks down i...
What could turn a biotech bet into a life-changing gain? This article breaks down how to spot this millionaire-maker ...
Peloton has faced a brutal selloff, but the story isn’t finished. This article dives into whether Peloton is broken o...
Iovance Biotherapeutics has shown dramatic swings, with recent gains masking a long history of volatility. This piece...
Oil markets look calm, but important shifts are quietly unfolding near the Strait of Hormuz. This article explains wh...